Didn't find what you were looking for?

Explore the latest resources from Actorius, a leading Oncology focused biotech company. Discover cutting-edge insights and innovations today! Resources Latest from Actorius Explore the latest updates, research perspectives, announcements, and stories shaping our work. Patents Publications Events Press Release Expert Insights 24 May 2026 Press Release The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 23 April 2026 Events AACR 2026 Highlights | April 17-22 | San Diego, California Highlights from AACR 2026 Read More 17 March 2026 Publications ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. Read More 17 March 2026 Publications ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Publications ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. Read More 17 March 2026 Publications AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. Read More 17 March 2026 Publications ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. Read More 17 March 2026 Publications AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Press Release Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 14 March 2026 Press Release डॉ. जयंत खंदारे के नेतृत्व में एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड करेगी कैंसर की पहचान और मेटास्टेसिस नियंत्रण में नई क्रांतिकारी पहल एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड, एक अग्रणी भारत-अमेरिकी जैव-प्रौद्योगिकी कंपनी है जो आधुनिक सर्कुलेटिंग टयूमर सेल्स (CTC) तकनीकों के माध्यम से ऑन्कोलॉजी के क्षेत्र में परिवर्तन ला रही है। कंपनी के संस्थापक, प्रबंध निदेशक और मुख्य वैज्ञानिक अधिकारी डॉ. जयंत खंदारे के दूरदर्शी नेतृत्व में कंपनी यह उल्लेखनीय प्रगति कर रही है। Read More 14 March 2026 Press Release Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 7 March 2026 Publications AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. Read More 20 February 2026 Events Meeting with our International KOLs Our team meeting with oncology KOLs from the US and Europe. Read More 5 February 2026 Press Release Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 27 January 2026 Publications Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... Read More 3 November 2025 Publications PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. Read More 3 November 2025 Publications Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. Read More 3 November 2025 Publications Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. Read More 3 November 2025 Publications Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. Read More 3 November 2025 Events ISLB 2025 | 1-3 November 2025 Actorius ISLB 2025 | 1-3 November 2025 Read More 20 October 2025 Patents Non-hemolytic compositions and methods of use for recovering disease-causing toxic constituents in the blood A non-hemolytic adsorbent composition designed to isolate, quantify, and remove disease-causing toxic constituents from blood, supporting disease identification, monitoring, and therapeutic efficacy validation. Read More 17 October 2025 Publications Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. Read More 17 October 2025 Events ESMO 2025 | 17–21 October 2025 Actorius at ESMO 2025 Read More 16 September 2025 Publications PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. Read More 16 September 2025 Publications Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. Read More 3 June 2025 Publications PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. Read More 3 June 2025 Publications Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. Read More 3 June 2025 Publications Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. Read More 3 June 2025 Publications Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. Read More 3 June 2025 Publications Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. Read More 9 May 2025 Publications Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. Read More 9 May 2025 Events ISMRC 2025 | 7-9 May, 2025 Actorius at ISMRC 2025 Read More 14 March 2025 Publications Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. Read More 25 November 2024 Publications ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. Read More 25 November 2024 Publications ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression. Read More 25 November 2024 Publications ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression. Read More 17 September 2024 Publications ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer. Read More 15 July 2024 Publications Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. Read More 29 June 2024 Publications Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. Read More 4 June 2024 Publications ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients. Read More 3 June 2024 Publications ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring. Read More 3 June 2024 Publications ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. Read More 3 June 2024 Publications ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. Read More 3 June 2024 Publications ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. Read More 10 April 2024 Publications AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. Read More 10 April 2024 Publications AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. Read More 4 April 2024 Publications Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. Read More 11 February 2024 Press Release Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Read More 24 October 2023 Publications ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. Read More 20 September 2023 Publications Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. Read More 20 July 2023 Publications Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). Read More 6 June 2023 Publications ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. Read More 6 June 2023 Publications ASCO 2023: Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh. A trial found CTCs in 60% of early-stage breast cancer patients, notably all HER2-positive cases, linking them to tumor grade. Send the next! Read More 19 April 2023 Publications AACR 2023: Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients. CTC analysis in 134 patients successfully detected PD-L1, HER2, and EGFR, proving its value as a real-time guide for targeted therapies. Read More 11 April 2023 Publications Manuscript: Chemical tunability of advanced materials used in the fabrication of micro/nanobots Review on chemically tunable micro- and nanobots for targeted nanomedicine, highlighting AI materials, applications, and biosafety considerations. Read More 6 March 2023 Press Release Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Read More 28 February 2023 Expert Insights TEDx Talk — Capturing cancer cells-Uncovering secrets for treatments by Aravindan Vasudevan – CEO, Actorius Innovations Aravindan discusses innovative cancer research in early detection, precision medicine, tumor modeling, and liquid biopsy for advanced cancer insights. Read More 13 February 2023 Patents Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Read More 15 January 2023 Publications AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. Read More 9 August 20222 Expert Insights OncoDiscover Available in India | Dr. Jayant Khandare OncoDiscover Available in India | Dr. Jayant Khandare Read More 28 August 2022 Expert Insights Revolutionary Blood Test Detects Cancer Relapse Early | Dr. Jayant Khandare Discover India's first approved, highly affordable blood test that detects cancer relapse and metastasis earlier than traditional CT or MRI scans. Developed by Dr. Jayant Khandare and clinically validated with Tata Memorial Hospital, this painless test catches circulating tumor cells before it's too late. Read More 9 August 2022 Expert Insights OncoDiscover Lab Walkthrough OncoDiscover Lab Walkthrough Read More 9 August 2022 Expert Insights Preventing Stage 4 Cancer: India’s Revolutionary Blood Test | Dr. Nirmal Raut Leading oncologists discuss OncoDiscover, India's first indigenous CTC blood test. By detecting Circulating Tumor Cells post-treatment, this affordable "Made in India" innovation catches cancer relapse before it reaches incurable Stage 4, dramatically changing the landscape of cancer care. Read More 9 August 2022 Press Release Revolutionary OncoDiscover® Blood Test for Early Cancer Detection - Metro News Gujarat Dr. Jayant Khandare interview with Metro News Gujarat Read More 9 August 2022 Expert Insights Made in India: The Low-Cost Blood Test Revolutionizing Cancer Care | Dr. Pankaj Chaturvedi Dr. Pankaj Chaturvedi (Director, ACTREC) and Dr. Jayant Khandare discuss OncoDiscover, India's first indigenous CTC blood test. By detecting cancer relapse earlier than traditional scans, this groundbreaking "Made in India" technology drastically lowers patient costs and paves the way for future medical innovations. Read More 1 July 2022 Publications Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. Read More 7 June 2022 Publications ASCO 2022: CTCs as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease. Study of 127 patients shows CTCs are a dynamic biomarker for monitoring disease progression and therapy response in advanced epithelial cancers. Read More 7 June 2022 Publications ASCO 2022: Machine learning (ML)–enabled, circulating tumor cell–based classification of patients for non-prerequisite adjuvant therapy. An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients. Read More 7 June 2022 Publications ASCO 2022: Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression. Read More 7 June 2022 Publications ASCO 2022: A feasibility study of EMF (erlotinib+methotrexate+5-fluorouracil) regimen in recurrent HNSCC and role of CTCs in assessment of outcomes. A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response. Read More 7 June 2022 Publications ASCO 2022: Correlation of circulating tumor cells as a positive interventional biomarker in cancer patients Ayurveda therapy significantly reduced CTC counts and improved quality of life in a study of 72 patients across 17 cancer types. Read More 27 April 2022 Publications Manuscript: Bioinspired Materials for Wearable Devices and Point-of-Care Testing of Cancer Raj Shankar Hazra, Md Rakib Hasan Khan, Narendra Kale, Tabassum Tanha, Jayant Khandare, Sabha Ganai, and Mohiuddin Quadir* Read More 18 February 2022 Publications Manuscript: Antibody mediated cotton-archetypal substrate for enumeration of circulating tumor cells and chemotherapy outcome in 3D tumors Cotton microfluidic substrate enables efficient CTC isolation, 3D tumor growth, and drug response testing for improved cancer diagnostics and therapy research. Read More 9 October 2021 Publications ESMO 2021: Validation of Cytokeratin (CK18) Protein Expression in Epithelial Cell lines and in Circulating Tumor Cells (CTCs) Study shows significant CK18 expression variance across different cancer cell lines and CTCs, highlighting the need for regulated enumeration tools. Read More 8 June 2021 Publications ASCO 2021: CTCs demonstrate a positive biomarker in head and neck squamous cell carcinoma (HNSCC) in tobacco consuming population of Bangladesh. A study in Bangladesh found CTCs in 64% of HNSCC patients with chronic tobacco history, suggesting CTCs as a screening tool for early cancer detection. Read More 22 April 2021 Patents Multifunctional magneto-polymeric nanosystems for rapid targeting, isolation, detection and simultaneous imaging of circulating tumor cells A multifunctional magneto-polymeric nanosystem for rapid targeting, isolation, detection, and imaging of circulating tumor cells to support cancer diagnostics and monitoring. Read More 18 December 2020 Publications Manuscript: Chemo-specific designs for the enumeration of circulating tumor cells: advances in liquid biopsy Review on chemo-specific nano/micro substrates for efficient CTC isolation, enabling liquid biopsy, metastasis detection, and real-time cancer monitoring. Read More 10 October 2020 Publications Manuscript: Cellulose Mediated Transferrin Nanocages for Enumeration of Circulating Tumor Cells for Head and Neck Cancer Magnetic transferrin-functionalized cellulose nanocages capture circulating tumor cells from blood, enabling liquid biopsy for early metastasis detection in head and neck cancer. Read More 11 August 2020 Expert Insights OncoDiscover Liquid Biopsy Technology | Clinical Significance of Circulating Tumor Cell Detection Highlights the clinical value of circulating tumor cell detection using OncoDiscover liquid biopsy technology for cancer diagnosis and patient monitoring. Read More 15 July 2020 Publications ASCO 2020: Device for the enumeration and continuous removal of circulating tumor cells in improving overall survival of epithelial cancer patients The POP blood fluidic device safely removes CTCs with up to 100% efficiency, offering a new therapeutic path to reduce metastasis and improve survival. Read More 23 April 2020 Press Release Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read More 15 March 2020 Publications ASCO 2020: Correlation of CTCs with disease progression in Indian oral cancer patients. In 230 OSCC patients, CTC counts correlated with cancer stage and aggressive features, proving CTCs are a reliable marker for disease stratification. Read More 26 February 2020 Patents Polymer based formulation for release of drugs and bioactives at specific GIT sites. A polymer-based formulation designed for targeted release of drugs and bioactives at specific gastrointestinal sites, including the stomach, intestine, and colon. Read More 29 August 2019 Press Release Early Detection of Cancer Recurrence Now Possible in Marathi A feature highlighting innovative liquid biopsy technology that enables early detection of cancer recurrence, with expert insights from Dr. Jayant Khandare of Actorius Innovations and Research in Marathi News Paper Read More 28 August 2019 Press Release Dr. Jayant Khandare – Interview Excerpts on DD Sahyadri Dr. Jayant Khandare shares insights on cancer diagnostics and liquid biopsy advancements in his edited interview on DD Sahyadri, aired by Doordarshan Sahyadri. Read More 24 August 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Press Release Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Press Release Startup Mantra: Making cancer detection more accessible and affordable to people Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume... Read More 4 June 2019 Publications ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Read More 22 March 2019 Press Release Actorius Innovations Featured on BBC News Click Kannada Actorius Innovations and Research was showcased on BBC News Click (Kannada edition), featuring an interview with Dr. Jayant Khandare and testimonials from leading oncologists including Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi, along with patient experiences. Read More 11 February 2018 Publications Manuscript: Optimizing Circulating Tumor Cells’ Capture Efficiency of Magnetic Nanogels by Transferrin Decoration Magnetic nanogels with optimized PEG–transferrin linkers achieve over 80% efficiency in selectively capturing circulating tumor cells from blood. Read More 17 January 2018 Publications Manuscript: Selective Cell Isolation by Transferrin Functionalized Silane– Carbon Soot Mediated Superhydrophobic Micropatterns Transferrin-functionalized wettability micropatterns enable selective cancer cell capture and real-time monitoring for diagnostics and recurrence detection. Read More 17 January 2017 Publications Manuscript: Biofunctionalized Capillary Flow Channel Platform Integrated with 3D Nanostructured Matrix to Capture Circulating Tumor Cells Continuous-flow 3D microchannel platform captures circulating tumor cells with ~90% efficiency, enabling liquid biopsy and real-time cancer monitoring. Read More 17 April 2015 Publications Manuscript:Calcium phosphate nanocapsule crowned multiwalled carbon nanotubes for pH triggered intracellular anticancer drug release Calcium phosphate–capped carbon nanotubes enable pH-triggered intracellular release of doxorubicin, preventing premature drug leakage and improving targeted cancer therapy. Read More 13 April 2015 Publications Manuscript: Self-propelled Carbon Nanotube Based Microrockets for Rapid Capture and Isolation of Circulating Tumor Cells Self-propelled CNT microrockets rapidly capture and magnetically isolate circulating tumor cells, enabling faster liquid biopsy and early cancer detection. Read More First Prev 1 Page 1 Next Last

Discover our dynamic leadership team at Actorius Innovations. Join our leadership team to drive innovation and growth today! Our Dynamic Leadership Team Meet the team and learn about our mission. Dr. Jayant Khandare Cofounder, MD & CSO Aravindan Vasudevan Cofounder & Director Rick Kamble Cofounder & Director Want to be a part of this dynamic team? Visit our Careers section to explore current opportunities that match your interests and expertise. Apply Now

Actorius at ESMO 2025 Events 17 October 2025 ESMO 2025 | 17–21 October 2025 Actorius at ESMO 2025 Some Glimpses from ESMO Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. Patents 13 February 2023 Devices and methods for recovering disease-causing toxic constituents in the blood A cost-effective, high-efficiency nanosystem for rapid circulating tumor cell enumeration. The present disclosure relates to non-hemolytic blood compatible devices and methods for capture, enumeration, removal of disease-causing agents from the blood and for the treatment of the cancer patients. The said devices incorporating non-hemolytic compositions are useful for removing disease-causing agents 'ex vivo' from cancer patient's blood to prevent/delay the proliferation of cancer. The devices retain disease-causing agents in particular Circulating Tumor Cells (CTCs), allowing the passage of other blood constituents retaining the viability of hematopoietic cells. Related patent documents WO/2023/229674 CA3255372 IN202527040253 View Patent Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC-based PD-L1 and EGFR detection supports targeted therapy in lung cancer. Publications 24 October 2023 ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. Background: Targeted molecular therapy and immunotherapy have revolutionized the treatment of advanced lung cancer (ALC). Although therapeutically significant, the outcome of immune checkpoint inhibitors (ICI) or tyrosine kinase inhibitors (TKI) depends on the presence of their respective targets in tumor cells. Evaluating targets based on solid tissue biopsy may often be misleading, particularly in progressive patients despite therapy administration. Additionally, tissue biopsy provides a static signature of target protein expression from an evolving tumor. The unmet need for dynamic detection and monitoring of actionable targets could be addressed by circulating tumor cells (CTCs). Here, we report on the utility of CTCs to detect actionable targets in advanced lung cancer (ALC) patients. Methods: We retrospectively analyzed 193 ALC patients for programmed death-ligand 1 (PD-L1) and EGFR expression on CTCs. CTCs were isolated using the Drug Controller General of India-approved OncoDiscover technology based on immunomagnetic targeting using anti-EpCAM antibodies and immunostaining with anti-EGFR and PD-L1 antibodies. CTCs were detected based on the expression of cytokeratins (CKs), absence of CD45, and prominent DAPI-stained nuclei. The presence or absence of EGFR and PD-L1 was determined using automated immunofluorescence microscopy. Results: Among the evaluated cohort, 67% of patients showed the presence of CTCs with a mean value of 4.2 (range: 1 to 62; SD = 10.65). The absence of CTCs in the remaining 33% of patients could be attributed to therapy response in clinically stable disease. Among all patients showing the presence of CTCs, 66% showed detectable expression of PD-L1, while 42% showed strong expression of EGFR. The presence of PD-L1 demonstrated a significant association with CTCs. Similarly, the expression of EGFR among detected CTCs showed high significance compared to reported tissue biopsy data in the literature. Conclusions: Detection of therapeutic targets on CTCs obtained from advanced lung cancer patients strongly indicates that these patients may qualify for anti-EGFR and PD-L1 targeted therapies. Systematic studies with larger sample sizes are required to further strengthen liquid biopsy–based detection of actionable targets. This approach could significantly benefit advanced lung cancer patients showing progressive disease despite chemotherapy or radiotherapy. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

HER2 analysis on CTCs enables real-time monitoring in metastatic breast cancer. Publications 10 April 2024 AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. Introduction: Breast cancer accounts for 12.5% of all new annual cancer cases worldwide. Cases classified as HER2-positive tend to proliferate, metastasize, and often lead to relapse. HER2 is one of the most valid tumor markers and is widely used as a diagnostic and prognostic biomarker in metastatic breast cancer (MBC). Thus, analyzing the expression of HER2 on circulating tumor cells (CTCs) can offer a real-time dynamic biomarker for guiding treatment options between endocrine therapy and chemotherapy in advanced breast cancer. Functional assays on CTCs with the HER2 biomarker offer evolving diagnostic opportunities, especially when tissue samples are not accessible or are inadequate. Methods: Retrospectively, blood samples from 179 breast cancer patients were analyzed for the presence of CTCs using the OncoDiscover® platform approved by the Drug Controller General of India (CDSCO). The platform consists of an immunomagnetic multi-component system mediated by anti-EpCAM antibodies. The isolated cells were immunostained using the nuclear dye DAPI along with CK18, CD45, and HER2 antibodies. CTCs were identified by the presence of HER2-positive, CK18-positive, DAPI-positive, and CD45-negative staining. Validation of HER2 expression on CTCs was analyzed based on the linear intensity gradients of fluorescence signals. CTCs were termed HER2-negative when weak or no detectable fluorescence signal was observed and HER2-positive when high fluorescence signals were detected. Results: Among the cohort of 179 patient samples, 63.68% of samples showed the presence of CTCs, with counts ranging from 1–7 CTCs. Among these, 47.84% of the detected CTCs showed HER2 expression. The mean fluorescence intensity value for HER2 expression in CTCs was found to be 3.23. The observed fluorescence intensity further emphasizes the robustness of CTCs as a viable source for molecular characterization. Conclusion: Integration of HER2 analysis on CTCs into the clinical assessment of metastatic breast cancer may offer a non-invasive, real-time strategy for tumor profiling and may help pave the way for more precise and tailored therapeutic interventions. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Actorius featured on BBC News Click Kannada with expert and patient insights. Press Release 22 March 2019 Actorius Innovations Featured on BBC News Click Kannada Actorius Innovations and Research was showcased on BBC News Click (Kannada edition), featuring an interview with Dr. Jayant Khandare and testimonials from leading oncologists including Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi, along with patient experiences. In this special feature on BBC News Click Kannada, Actorius Innovations and Research highlights its advancements in cancer diagnostics and liquid biopsy technology. Dr. Jayant Khandare shares insights into the science and vision behind the innovation, while renowned experts Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi provide clinical perspectives on its impact. The segment also includes powerful patient testimonials, underscoring the real-world significance of early and minimally invasive cancer detection. Watch the video Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

CTC counts correlate with OSCC stage and aggressive pathological features in India. Publications 15 March 2020 ASCO 2020: Correlation of CTCs with disease progression in Indian oral cancer patients. In 230 OSCC patients, CTC counts correlated with cancer stage and aggressive features, proving CTCs are a reliable marker for disease stratification. Background Head and neck squamous cell carcinoma is the leading cancer in India, with oral squamous cell carcinoma (OSCC) as the most frequent subtype. OSCC is classified as a locoregional disease, and its increased frequency is attributed to a lack of effective biomarkers compared to other epithelial cancers. At the time of diagnosis, above 50% of cases present with advanced-stage disease and are predisposed to treatment failure despite appropriate intervention. Thus, early diagnosis of OSCC can significantly reduce the disease burden. Here, we describe a regulatory-approved method to establish the presence of circulating tumor cells (CTCs) in Indian OSCC patients and its positive correlation with various clinicopathological parameters, suggesting the potential use of CTCs as a significant parameter to stratify oral cancer with respect to disease advancement. Methods In a cross-sectional observational study, 230 OSCC patients at different pathological stages of the disease and treatment modes were enrolled. CTCs were isolated using the approved OncoDiscover liquid biopsy technology (approved by the Drug Controller General of India), a platform based on immunomagnetic CTC enumeration. CTCs were detected for CK18 presence and well-defined, DAPI-stained nuclei. Enumerated CTCs were subsequently analyzed for various clinicopathological parameters such as pathological stage (pStage), extra-capsular spread (ECS), lymphovascular emboli (LVE), perineural invasion (PNI), and depth of invasion (DOI). CTC cut-off values were obtained to differentiate early vs. advanced stages with respect to different clinical stages and parameters. Results CTCs of OSCC patients correlated positively with cancer stages (clinical as well as pathological) as well as aggressive pathological features. In the presence of aggressive pathological features that often suggest a poor disease outcome, we observed a 25–50% increase in CTC numbers. Early-stage, treatment-naive patients had a lower number of CTCs. The mean CTC number in advanced-stage patients was 50% higher than in early-stage OSCC patients. Conclusions Considering the positive correlation of CTC numbers with various pathophysiological features, CTCs can be contemplated as a reliable parameter to predict disease outcome in oral cancer. The consistent presence of CTCs across all disease stages also suggests the probable nature of OSCC as a biological systemic disease. Clinical Trial Information CTRI/2018/03/012905. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Discover our groundbreaking research in Oncology. Explore our publications to see research that matters. Stay informed with our latest insights. Publications Research That Shapes the Future of Oncology Access studies, scientific papers, and published findings advancing cancer diagnostics and care. 17 March 2026 Read More ASCO 2026 : Association of circulating tumor cells with PD-L1 expression and clusters in confirmative tumor thrombus in selective solid cancers. Study shows circulating tumor cells with PD-L1 expression in tumor thrombus patients, indicating active dissemination and potential metastatic risk. 17 March 2026 Read More ASCO 26: Assessment of circulating tumor cells and clusters expressing PD-L1 in urological cancers High prevalence of PD-L1–positive circulating tumor cells in urological cancers, especially prostate cancer, indicating minimal residual disease and recurrence risk. 17 March 2026 Read More ASCO 2026: Comparative enumeration of circulating tumor cells with PD-L1 over expression using anti EpCAM antibody to N-Cadherin in solid cancers Dual EpCAM and N-cadherin profiling improves circulating tumor cell detection, enhancing minimal residual disease surveillance and identifying metastasis-prone cells. 17 March 2026 Read More AACR 2026: Over expressing PD-L1 circulating tumor cells with clusters in prostate cancer patients Study shows high prevalence of PD-L1–positive circulating tumor cells in prostate cancer, highlighting their value for monitoring disease progression and immune evasion. 17 March 2026 Read More ASCO 2026: Continual depletion of circulating tumor cells using an automated device enriched with affinity glass bead substrates in breast and CRC patient's whole blood. Automated OncoMetastat device captures and depletes CTCs in colorectal and breast cancer, aiding detection of minimal residual disease and metastasis risk. 17 March 2026 Read More AACR 2026: Depletion of circulating tumor cells using an automated device using non-hemolytic affinity-based substrates Actorius Innovations presents accepted research abstracts at the AACR Annual Meeting 2026, highlighting advances in cancer diagnostics, therapeutics and liquid biopsy. 7 March 2026 Read More AACR 2020: Clinical correlation of circulating tumor cells as a blood marker in Indian head and neck cancer patients. A study of 350 Indian HNC patients confirms CTCs correlate with nodal stage and aggressive features, validating their use as a clinical staging marker. 27 January 2026 Read More Manuscript: Real-Time Therapy Response Monitoring Using Surface Biomarkers on Circulating Tumor Cells Circulating tumor cells (CTCs), cancer cells shed from primary tumors into the bloodstream, are emerging as dynamic, non-invasive biomarkers for real-time cancer monitoring, especially when tissue biopsies are inaccessible or inadequate... 3 November 2025 Read More PD-L1 over-expression on Circulating Tumor Cells in Endometrial Cancer Patients Khandare J, Ghadyalpatil N, Raja T, Velukuru S, Jadhav V, Satape R, Shinde S, Ashturkar A, Dattatreya P, Vasudevan A Actorius Innovations And Research, Pune, Maharashtra, India; Apollo Cancer Institute, Hyderabad, Telangana, India; Apollo Cancer Centre, Chennai, Tamil Nadu, India; Aster CMI Hospital, Bangaluru, Karnataka, India; Renova Soumya Cancer Center, Hyderabad, Telangana, India. 3 November 2025 Read More Assessment of PD-L1 Expression on Circulating Tumor Cells and Clusters in Gastric Cancer Patients Circulating tumor cells with PD-L1 expression and clusters are common in gastric cancer, indicating minimal residual disease and recurrence risk. 3 November 2025 Read More Automated Continual Flow Device to Deplete Circulating Tumor Cells using Spiral Cartridge Mediated by Antibody and Transferrin Glass Substrate Automated OncoMetastat device captures and depletes circulating tumor cells from whole blood safely, supporting extracorporeal cancer therapy and monitoring. 3 November 2025 Read More Association of Circulating Tumor Cell Dynamics with Patient-Reported Cancer Worry in Post-Surgical Breast Cancer Patients Circulating tumor cell monitoring before and after breast cancer surgery reveals minimal residual disease and correlates with post-surgical cancer worry. 17 October 2025 Read More Circulating Biomarkers Reveal their Complementary Association in Primary and Metastatic Colorectal Cancer Patients Combined CTC and ctDNA analysis reveals strong prognostic value for monitoring progression and metastasis in colorectal cancer patients. 16 September 2025 Read More PD-L1 overexpression on circulating tumor cells and CTC clusters: A potential biomarker across solid carcinomas Correlation of CTC detection, PD-L1 expression, and CTC clusters highlights biomarkers for minimal residual disease and cancer progression monitoring. 16 September 2025 Read More Profiling of PD-L1 and HER2 over expression on cancer cells using AI based macro-driven automation AI-based image analysis rapidly profiles circulating tumor cells, quantifying morphology and biomarkers like PD-L1 and HER2 for cancer research. 3 June 2025 Read More PD-L1 expression on circulating tumor cells and CTC clusters as a minimal cellular disease in breast cancer patients. This breast cancer study shows high prevalence of PD-L1–positive circulating tumor cells, supporting their role in minimal residual disease and metastasis risk. 3 June 2025 Read More Circulating tumor cells and clusters exhibiting expression of PD-L1 in colorectal patients. High prevalence of PD-L1–positive circulating tumor cells in colorectal cancer highlights their role in minimal residual disease and recurrence monitoring. 3 June 2025 Read More Use of dynamic blood flow device with conjugated affinity ligands on glass substrate to capture circulating tumor cells in cancer patients. Continuous-flow 3D glass substrate device safely captures circulating tumor cells, demonstrating potential to reduce metastasis and improve cancer survival. 3 June 2025 Read More Quadrant of co-occurrence of circulating tumor DNA and PD-L1 expression on circulating tumor cells in monitoring disease aggressiveness and metastasis in lung cancer. Combined ctDNA and PD-L1–positive CTC analysis improves monitoring of metastasis, minimal residual disease, and treatment response in lung cancer. 3 June 2025 Read More Comparative analysis of circulating tumor cell distribution with PD-L1 expression in baseline and follow ups patients across cancer types. This multi-cancer study shows CTC and PD-L1 prevalence across Indian patients, supporting minimal residual disease monitoring and personalized cancer care. 9 May 2025 Read More Accounts of circulating tumor cells and CTC clusters with PD-L1 expression in sarcoma patients Study shows circulating tumor cells with PD-L1 expression and clusters in sarcoma, indicating minimal residual disease and need for long-term monitoring. 14 March 2025 Read More Manuscript: The impact of co-occurring tumor suppressor mutations with mEGFR as early indicators of relapse in lung cancer A set of 17 co-occurring TSG mutations has been identified as key biomarkers for early relapse in mEGFR lung adenocarcinoma. Longitudinal genomic monitoring, with a focus on clonal evolution, offers valuable insights that can inform personalized treatment strategies and potentially improve patient outcomes. 25 November 2024 Read More ISLB 2024: Transit of Circulating Tumor Cells (CTC) Post Radiotherapy at Irradiated Tumor Regions in Pan-cancer Patients Study links radiotherapy exposure with circulating tumor cells and PD-L1 expression, indicating possible minimal residual disease and metastatic risk. 25 November 2024 Read More ISLB 2024: Comprehensive Analysis of ctDNA and CTCs Reveals Resistance signatures and Correlations with PET Scan Outcomes in Cancer Patients Integrated ctDNA and CTC analysis correlates with PET-CT outcomes to reveal treatment resistance and aggressive cancer progression. 25 November 2024 Read More ISLB 2024: Expression of Programmed Death - Ligand 1 as a dynamic biomarker on circulating tumor cells in pancreatic cancer patients CTC detection with PD-L1 overexpression reveals aggressive pancreatic cancer and potential biomarker value for monitoring metastasis and disease progression. 17 September 2024 Read More ESMO 2024: True single-circulating tumor cell genomics reveals enriched therapy-resistance signatures in advanced colorectal cancer patients Single CTC genomics reveals actionable mutations and therapy resistance signatures not detected in paired ctDNA in advanced colorectal cancer. 15 July 2024 Read More Manuscript: Inverse 3D ‘lab-on-a-chip’ polymeric microfilms for selective capture of circulating tumor cells from patients' blood Inverse 3D lab-on-chip microfilms for selective CTC capture from blood. 29 June 2024 Read More Manuscript: Circulating Tumor Cells as Biomarkers for Relapse Detection in Rectal Cancer with Liver Metastasis: Insights from a Case Report In this case report we demonstrate the utility of CTC as a sensitive marker to detect MRD. CTCs play a crucial role in the context of MRD in colorectal cancer, offering a valuable biomarker for prognosis, treatment monitoring, and early detection of recurrence. 4 June 2024 Read More ASCO 2024: Effect of circulating tumor cells in clinically stable patients on the conundrum of recurrence with cellular residual disease. CTC detection with PD-L1 expression reveals residual disease despite negative radiological findings in treated cancer patients. 3 June 2024 Read More ASCO 2024: Effect of circulating tumor cells (CTC) and CTC clusters with PD-L1 dynamic biomarker on cellular burden in patients with ovarian cancer. CTCs with PD-L1 expression in ovarian cancer reveal minimal residual disease and may guide immunotherapy and early metastasis monitoring. 3 June 2024 Read More ASCO 2024: Measure of minimal residual burden on CTCs with over-expression of PD-L1 as a dynamic biomarker in patients with colorectal cancer. CTC detection with PD-L1 expression in colorectal cancer reveals minimal residual disease and supports personalized treatment strategies. 3 June 2024 Read More ASCO 2024: Impact of ctDNA genomic mutations and CTCs biomarker duo on clinical concordance in localized, progressive, and metastatic disease. Dual biomarker analysis of ctDNA and circulating tumor cells reveals disease progression and metastasis across multiple cancer types. 3 June 2024 Read More ASCO 2024: Association of complementing ctDNA and CTCs load on stable and progressive disease in treated patients. Complementary ctDNA and CTC biomarkers reveal minimal residual disease and predict cancer progression after curative-intent treatment. 10 April 2024 Read More AACR 2024: Distribution prophecy of circulating tumor cell clusters in CTC populace patients of epithelial cancers Large-scale analysis of circulating tumor cells and clusters reveals their role in predicting aggressive epithelial cancers and treatment resistance. 10 April 2024 Read More AACR 2024: Evaluation of HER-2 expression on circulating tumor cells as a real time biomarker in advanced breast cancer HER2 analysis on circulating tumor cells using the OncoDiscover® platform enables real-time, non-invasive profiling for improved metastatic breast cancer treatment decisions. 4 April 2024 Read More Manuscript: CTC together with Shh and Nrf2 are prospective diagnostic markers for HNSCC Study links Shh/Nrf2 overexpression with circulating tumor cells in HNSCC, highlighting their potential as biomarkers for early detection and survival prediction. 24 October 2023 Read More ESMO 2023: Expression of PD-L1 and EGFR on circulating tumor cells in advanced Lung cancer patients CTC analysis using OncoDiscover® enables dynamic detection of PD-L1 and EGFR targets in advanced lung cancer, supporting personalized targeted and immunotherapy decisions. 20 September 2023 Read More Manuscript: Magnetically-activated, nanostructured cellulose for efficient capture of CTCs from the blood sample of head and neck cancer patients Study compares CNC and CNF cellulose nanostructures for EpCAM-based CTC capture in head and neck cancer, enabling affordable real-time cancer monitoring. 20 July 2023 Read More Manuscript: Role of circulating tumour cells (CTCs) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) This study highlights the utility of CTCs as a disease progression monitoring tool in recurrent HNSCC patients. Our findings suggest the potential clinical utility of CTCs and the need for further exploration in upfront settings of the disease as well (NCT: CTRL/2020/02/023378). 6 June 2023 Read More ASCO 2023: Effect of circulating tumor cells distribution in treatment naive and treated patients with advance stage breast cancer on disease burden. A study of 417 breast cancer patients shows tracking circulating tumor cells (CTCs) effectively monitors therapy response and recurrence risk. 6 June 2023 Read More ASCO 2023: Circulating tumor cells (CTCs) detection and isolation in different subtypes of early-stage breast cancer patients from Bangladesh. A trial found CTCs in 60% of early-stage breast cancer patients, notably all HER2-positive cases, linking them to tumor grade. Send the next! 19 April 2023 Read More AACR 2023: Detection of PD-L1, HER2 and EGFR on circulating tumor cells in carcinoma patients. CTC analysis in 134 patients successfully detected PD-L1, HER2, and EGFR, proving its value as a real-time guide for targeted therapies. 11 April 2023 Read More Manuscript: Chemical tunability of advanced materials used in the fabrication of micro/nanobots Review on chemically tunable micro- and nanobots for targeted nanomedicine, highlighting AI materials, applications, and biosafety considerations. 15 January 2023 Read More AACR 2023: Abstract PR007: Comprehensive ctDNA profiling reveals potential metastatic genomic signatures in treatment-naive early-stage breast cancer patients Comprehensive ctDNA profiling and CTC analysis in early-stage breast cancer identifies driver mutations to predict early metastasis. 1 July 2022 Read More Manuscript: Circulating tumor cells as a predictor for poor prognostic factors and overall survival in treatment nay¨ve oral squamous cell carcinoma patients Preoperative circulating tumor cell levels strongly correlate with metastasis, disease severity, and reduced survival in oral squamous cell carcinoma patients. 7 June 2022 Read More ASCO 2022: CTCs as a biomarker for monitoring: Disease progression, treatment response, and minimal residual disease. Study of 127 patients shows CTCs are a dynamic biomarker for monitoring disease progression and therapy response in advanced epithelial cancers. 7 June 2022 Read More ASCO 2022: Machine learning (ML)–enabled, circulating tumor cell–based classification of patients for non-prerequisite adjuvant therapy. An XGBoost ML model using CTCs and clinical data achieved 84% accuracy in predicting the need for adjuvant therapy in 380 HNSCC patients. 7 June 2022 Read More ASCO 2022: Extracorporeal microchannel device to capture and eliminate circulating tumor cells from cancer patient’s blood. A 3D-printed G-EpCAM device successfully captured over 85% of CTCs with minimal hemolysis, offering a new way to stem metastatic progression. 7 June 2022 Read More ASCO 2022: A feasibility study of EMF (erlotinib+methotrexate+5-fluorouracil) regimen in recurrent HNSCC and role of CTCs in assessment of outcomes. A phase II trial shows EMF triplet therapy is a safe, effective option for HNSCC, with CTCs serving as a promising biomarker for therapy response. 7 June 2022 Read More ASCO 2022: Correlation of circulating tumor cells as a positive interventional biomarker in cancer patients Ayurveda therapy significantly reduced CTC counts and improved quality of life in a study of 72 patients across 17 cancer types. First Prev 1 Page 1 Next Last

OncoDiscover: affordable, rapid CTC platform for HNC patients in developing nations. Publications 4 June 2019 ASCO 2019: Correlation of CTCs with disease progression in Indian oral cancer patients "OncoDiscover" is a fast, highly sensitive, and affordable (~$120) CTC nanosystem validated in 100 HNC patients to meet global medical needs. Background Liquid biopsy technologies are often unaffordable and unavailable in developing countries, despite these regions having the highest cancer burden and mortality rates. Current circulating tumor cell (CTC) technologies face significant clinical concerns, including non-specificity, low efficiency, high blood volume requirements, long turnaround times, and exorbitant costs (~$900–$1,400). We report an extremely low-cost, innovative nanosystem for the rapid enumeration of CTCs with higher specificity and efficiency. Methods We designed a nanosystem mediated by the conjugation of anti-EpCAM through a multi-reactive glutathione spacer, a carbon allotrope, and an amine-terminated dendrimer. The platform was evaluated for enhanced aqueous dispersibility and increased interaction with CTCs for rapid isolation and enumeration in 100 head and neck cancer (HNC) patients. These patients had various primary tumor sub-sites, including the oral cavity, larynx, hypopharynx, oropharynx, nasopharynx, salivary gland, and thyroid. The captured cells were immunostained, and the optimal fluorescence acquisition intensity was validated by accounting for CTCs with CK18 protein expression. Our method achieved the complete elimination of false-positive normal cell (NC) counts. The analysis was performed using only 1.5 ml of collected blood samples. Results The CTC distribution in the cohort study ranged from 1 to 85 cells per 1.5 ml of blood. In more than 80% of patients' CTCs, the quantitative estimation of anti-CK18 protein overexpression indicated an intensity approximately 10-fold higher than that of normal cells. Compared to treatment-naive, recurrent, and disease-free patients, the spread of CTC numbers across the clinical range appeared to be tight (close to the mean value). The CTC enumeration sensitivity linearity was ~99.2%, and the complete enumeration process time was under 3 hours per 1.5 ml of blood. Consequently, an efficient, rapid, and affordable CTC platform was designed and clinically validated. Conclusions The "OncoDiscover" liquid biopsy technology for CTC enumeration is poised to revolutionize the field due to its high sensitivity and affordability (~$120). It addresses a major unmet medical need in the developing world. Know more Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Liquid biopsy may replace invasive procedure to detect cancer Press Release 23 April 2020 Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read the article Stay One Step Ahead of Cancer. Get the latest news and innovations from Actorius delivered straight to your inbox. Subscribe for regular updates Email* Yes, subscribe me for regular updates. * Subscribe

Discover the latest press releases, media coverage, and important announcements from Actorius Innovations and Research and see how we're making headlines in the industry. News & Press Updates News, Media & Announcements Latest press releases, media coverage, and important announcements from Actorius Innovations and Research. Read More 24 May 2026 The Hidden Threat of a Single Cell: Dr. Jayant Khandare on How One Circulating Tumor Cell Can Restart the Cancer Journey The deadliest cancer threat may be invisible — just one surviving cell can be enough to restart the disease journey. Read More 17 March 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 17 March 2026 Actorius Innovations pioneers' oncology care with its OncoDiscover and OncoMetastat solutions Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Read More 14 March 2026 डॉ. जयंत खंदारे के नेतृत्व में एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड करेगी कैंसर की पहचान और मेटास्टेसिस नियंत्रण में नई क्रांतिकारी पहल एक्टोरियस इनोवेशन्स ऍंड रिसर्च प्राइवेट लिमिटेड, एक अग्रणी भारत-अमेरिकी जैव-प्रौद्योगिकी कंपनी है जो आधुनिक सर्कुलेटिंग टयूमर सेल्स (CTC) तकनीकों के माध्यम से ऑन्कोलॉजी के क्षेत्र में परिवर्तन ला रही है। कंपनी के संस्थापक, प्रबंध निदेशक और मुख्य वैज्ञानिक अधिकारी डॉ. जयंत खंदारे के दूरदर्शी नेतृत्व में कंपनी यह उल्लेखनीय प्रगति कर रही है। Read More 14 March 2026 Dr. Jayant Khandare Leads Actorius with Pathbreaking Innovations in Cancer Detection and Metastasis Control Actorius Innovations and Research Pvt Ltd, a pioneering Indo-US biotechnology company revolutionizing oncology through advanced circulating tumor cell (CTC) technologies, continues to make significant strides under the visionary leadership of Dr. Jayant Khandare, Founder, Managing Director, and Chief Scientific Officer. Read More 5 February 2026 Actorius and ACTREC Partner to Advance Clinical Cancer Research. A collaborative research initiative to study the practical utility of Circulating Tumor Cells and their capture and depletion from patient's blood as possible aid to adjunct therapeutics. Read More 11 February 2024 Magnetic nanocrystals capture tumour cells from blood samples These nanomaterials could speed up discovery of anti-cancer drugs Read More 6 March 2023 Pune start-up gets US patent for delivering drugs to site-specific organs The patent was granted to Actorius Innovations and Research and its team that designed capsule shells using natural polymer to obtain a delayed release profile suitable for delivery of drugs to colon and rectum, said Dr Jayant Khandare, founder-director and Chief Scientific Officer of the start-up. Read More 9 August 2022 Revolutionary OncoDiscover® Blood Test for Early Cancer Detection - Metro News Gujarat Dr. Jayant Khandare interview with Metro News Gujarat Read More 23 April 2020 Times of India | Liquid biopsy may replace invasive procedure to detect cancer: Experts Liquid biopsy may replace invasive procedure to detect cancer: Experts Read More 29 August 2019 Early Detection of Cancer Recurrence Now Possible in Marathi A feature highlighting innovative liquid biopsy technology that enables early detection of cancer recurrence, with expert insights from Dr. Jayant Khandare of Actorius Innovations and Research in Marathi News Paper Read More 28 August 2019 Dr. Jayant Khandare – Interview Excerpts on DD Sahyadri Dr. Jayant Khandare shares insights on cancer diagnostics and liquid biopsy advancements in his edited interview on DD Sahyadri, aired by Doordarshan Sahyadri. Read More 24 August 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Pune scientists discover tech, first in India, to detect early spread of cancer. The new "OncoDiscover" technology discovered by a team led by Dr Jayant Khandare not only detects the early spread of cancer but doctors say it can also speed up the cancer detection process… Read More 24 August 2019 Startup Mantra: Making cancer detection more accessible and affordable to people Launching ‘OncoDiscover Liquid Biopsy Test’, a minimally invasive test which can be performed multiple times requiring 1.5ml blood volume... Read More 22 March 2019 Actorius Innovations Featured on BBC News Click Kannada Actorius Innovations and Research was showcased on BBC News Click (Kannada edition), featuring an interview with Dr. Jayant Khandare and testimonials from leading oncologists including Dr. Kumar Prabhash and Dr. Pankaj Chaturvedi, along with patient experiences. First Prev 1 Page 1 Next Last